ESC 2020

Episodes 1-16 of 16

Strong evidence for colchicine in patients with chronic coronary disease
Strong evidence for colchicine in patients with chronic coronary disease
ESC 2020
Strong evidence for colchicine in patients with chronic coronary disease
- Aernoud Fiolet, MD
- Aernoud Fiolet, MD, PhD
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
ESC 2020
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
- Prof. Freek Verheugt, MD
Incredible consistency between two SGLT2i trials in HFrEF
Incredible consistency between two SGLT2i trials in HFrEF
ESC 2020
Incredible consistency between two SGLT2i trials in HFrEF
- Milton Packer, MD
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
ESC 2020
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
- Prof. Renato D. Lopes, MD, PhD
Updates in the 2020 AF guidelines
Updates in the 2020 AF guidelines
ESC 2020
Updates in the 2020 AF guidelines
- Isabelle van Gelder, MD, PhD
Advantages of the digital 2020 ESC Congress
Advantages of the digital 2020 ESC Congress
ESC 2020
Advantages of the digital 2020 ESC Congress
- Prof. Barbara Casadei, MD
BP lowering should be considered irrespective of prior CVD or baseline SBP
BP lowering should be considered irrespective of prior CVD or baseline SBP
ESC 2020
BP lowering should be considered irrespective of prior CVD or baseline SBP
- Kazem Rahimi, MD
A step ahead in the management of HFmrEF and HFpEF
A step ahead in the management of HFmrEF and HFpEF
ESC 2020
A step ahead in the management of HFmrEF and HFpEF
- Prof. Burkert Pieske
Colchicine reduces primary outcome in chronic coronary disease
Colchicine reduces primary outcome in chronic coronary disease
ESC 2020
Colchicine reduces primary outcome in chronic coronary disease
- Mark Nidorf, MD
Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI
Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI
ESC 2020
Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI
- Prof. Menno Huisman
Nephroprotective effects with SGLT2i in CKD patients
Nephroprotective effects with SGLT2i in CKD patients
ESC 2020
Nephroprotective effects with SGLT2i in CKD patients
- Prof. Hiddo Heerspink, PhD
Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated
Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated
ESC 2020
Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated
- Prof. Barbara Casadei, MD
Aspirin superior to DAPT for bleeding in patients treated with TAVI
Aspirin superior to DAPT for bleeding in patients treated with TAVI
ESC 2020
Aspirin superior to DAPT for bleeding in patients treated with TAVI
- Jorn Brouwer, MD
Early rhythm control in AF patients improves outcomes
Early rhythm control in AF patients improves outcomes
ESC 2020
Early rhythm control in AF patients improves outcomes
- Prof. Paulus Kirchhof, MD
Remarkably similar findings with another SGLT2i in HFrEF
Remarkably similar findings with another SGLT2i in HFrEF
ESC 2020
Remarkably similar findings with another SGLT2i in HFrEF
- Prof. John McMurray, MD
Succes with SGLT2 inhibitor in HFrEF for all three end points
Succes with SGLT2 inhibitor in HFrEF for all three end points
ESC 2020
Succes with SGLT2 inhibitor in HFrEF for all three end points
- Milton Packer, MD

Episodes 1-16 of 16

Title

Share on ReachMD